Pharma

Why Is Thermo Fisher’s CDMO Business Set for Major Growth?
Manufacturing Why Is Thermo Fisher’s CDMO Business Set for Major Growth?

Understanding the CDMO Industry and Thermo Fisher’s Role Imagine a world where the development of life-saving drugs hinges on partnerships that streamline innovation and production at an unprecedented scale, a reality embodied by the contract development and manufacturing organization (CDMO)

FDA Delays Cell and Gene Therapy Approvals Over CMC Issues
Manufacturing FDA Delays Cell and Gene Therapy Approvals Over CMC Issues

In the rapidly advancing realm of medical innovation, cell and gene therapies stand out as potential game-changers for treating life-threatening diseases, yet they face formidable obstacles on the path to market. The U.S. Food and Drug Administration (FDA) has increasingly postponed or denied

Drug Factories at Risk in Disaster-Prone U.S. Areas
Manufacturing Drug Factories at Risk in Disaster-Prone U.S. Areas

In a nation heavily reliant on a steady supply of life-saving medications, the stark reality that many pharmaceutical manufacturing facilities are situated in regions increasingly vulnerable to natural disasters raises profound concerns. From hurricanes tearing through coastal areas to wildfires

How Is 3D Systems Pioneering Regenerative Medicine in 2025?
Manufacturing Technology How Is 3D Systems Pioneering Regenerative Medicine in 2025?

In a world where organ shortages and chronic diseases continue to challenge healthcare systems globally, 3D Systems, a titan in additive manufacturing, is stepping up with groundbreaking solutions in regenerative medicine. This innovative field, which focuses on creating living tissues and organs

Trump's SAPIR Initiative Reshapes US Pharma Manufacturing
Manufacturing Trump's SAPIR Initiative Reshapes US Pharma Manufacturing

The U.S. pharmaceutical sector finds itself at a critical juncture with the rollout of President Donald J. Trump’s SAPIR (Strategic Active Pharmaceutical Ingredients Reserve) Initiative, a groundbreaking policy introduced via an Executive Order on August 13 of this year. This ambitious plan seeks

How Will Viral Vector and Plasmid DNA Markets Grow by 2035?
Manufacturing How Will Viral Vector and Plasmid DNA Markets Grow by 2035?

The viral vector and plasmid DNA manufacturing market stands at the threshold of a transformative era, propelled by an escalating demand for gene therapies, vaccines, and personalized medical solutions that are reshaping the landscape of healthcare. These technologies, essential for delivering

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later